MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
about
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemiaIL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing StudyNew Therapeutic Strategies in Acute Lymphocytic Leukemia.Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.The genetics and molecular biology of T-ALL.Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells.The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An UpdateSTAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cellsCooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia
P2860
Q28075211-EF607B6D-0B3A-43D4-999D-B2AC38BBFB90Q28555124-4427BDE3-B2E8-47F4-B836-64A2E2EF1825Q30252776-0C976FC1-8AA3-4CE2-861F-7DC075A759E4Q38602949-DA915E74-5CAC-4D9B-B309-549681429164Q38707261-CF4833CC-7905-4DCE-A137-CE79BAD0514FQ38756560-C6218BC2-7D29-4B69-B3AA-0224B2C58ACEQ38796883-957E6A43-E922-4C07-9920-2A3ED7EECA42Q38856941-332BE464-8651-41A0-804C-53F870FC585EQ39099555-19CC4F17-654A-46CA-8E2E-8945F420D095Q47122504-C952F403-9ADC-43BC-A03B-7E66A5A03DB1Q48027760-0BCF04A4-7E94-4C43-AF7B-C7E64337BFABQ52593673-CD9B38C8-12E2-44EE-A997-B8310C1F7D7DQ52668197-F1D116D6-FD37-424B-952A-7DE20E69EF81Q56378380-2E92AFD7-69AA-4993-A1EF-AB3D1992D0C5Q58762852-0C5F1C5D-A8DB-43E1-9E1C-CEF73EFF2785Q58785945-AB0EB6C1-0F89-42E3-B01F-A88D83EF147E
P2860
MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
MEK and PI3K-AKT inhibitors sy ...... acute lymphoblastic leukemia.
@en
MEK and PI3K-AKT inhibitors sy ...... acute lymphoblastic leukemia.
@nl
type
label
MEK and PI3K-AKT inhibitors sy ...... acute lymphoblastic leukemia.
@en
MEK and PI3K-AKT inhibitors sy ...... acute lymphoblastic leukemia.
@nl
prefLabel
MEK and PI3K-AKT inhibitors sy ...... acute lymphoblastic leukemia.
@en
MEK and PI3K-AKT inhibitors sy ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
MEK and PI3K-AKT inhibitors sy ...... l acute lymphoblastic leukemia
@en
P2093
G J R Zaman
J A P Spijkers-Hagelstein
J C M Uitdehaag
J G C A M Buijs-Gladdines
J van der Zwet
K Canté-Barrett
R C Buijsman
P2860
P2888
P304
P356
10.1038/LEU.2016.83
P577
2016-04-22T00:00:00Z
P5875
P6179
1012796415